Knight Net Debt from 2010 to 2026
| GUD Stock | CAD 6.32 0.35 5.86% |
Net Debt | First Reported 2014-03-31 | Previous Quarter 26.9 M | Current Value 24.4 M | Quarterly Volatility 179.7 M |
Check Knight Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Knight Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 64.1 M, Interest Expense of 9.2 M or Selling General Administrative of 26.3 M, as well as many indicators such as Price To Sales Ratio of 1.59, Dividend Yield of 0.31 or PTB Ratio of 1.11. Knight financial statements analysis is a perfect complement when working with Knight Therapeutics Valuation or Volatility modules.
Knight | Net Debt |
Evaluating Knight Therapeutics's Net Debt across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Knight Therapeutics's fundamental strength.
Latest Knight Therapeutics' Net Debt Growth Pattern
Below is the plot of the Net Debt of Knight Therapeutics over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Knight Therapeutics' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Knight Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Debt | 10 Years Trend |
|
Net Debt |
| Timeline |
Knight Net Debt Regression Statistics
| Arithmetic Mean | (128,773,986) | |
| Coefficient Of Variation | (133.61) | |
| Mean Deviation | 138,573,357 | |
| Median | (37,006,252) | |
| Standard Deviation | 172,054,811 | |
| Sample Variance | 29602.9T | |
| Range | 525.3M | |
| R-Value | 0.15 | |
| Mean Square Error | 30833.1T | |
| R-Squared | 0.02 | |
| Significance | 0.56 | |
| Slope | 5,227,330 | |
| Total Sum of Squares | 473645.7T |
Knight Net Debt History
About Knight Therapeutics Financial Statements
Knight Therapeutics investors utilize fundamental indicators, such as Net Debt, to predict how Knight Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Debt | -35.2 M | -37 M | |
| Net Debt To EBITDA | (0.55) | (0.52) |
Other Information on Investing in Knight Stock
Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.